NCT05776134 2026-04-08
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
Gilead Sciences
Available
Clinical Trials
50 trialsNCT06915766 2026-03-09
Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
Cogent Biosciences, Inc.
Available
NCT06799221 2026-02-27
Expanded Access Program for OOS Obe-cel
Autolus Limited
Available
NCT06439966 2026-02-12
Expanded Access to ABBV-787
AbbVie
No longer available
NCT03123029 2026-01-30
Expanded Access to Venetoclax
AbbVie
Available
NCT00590915 2026-01-23
EMTP
Phoenix Children's Hospital
No longer available
NCT07346105 2026-01-16
Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies
Orca Biosystems, Inc.
Temporarily not available
NCT03601442 2025-12-05
CTL019 Out of Specification MAP for ALL or DLBCL Patients
Novartis
Available
NCT04360005 2025-12-05
Managed Access Programs for ABL001, Asciminib
Novartis
Available
NCT01881334 2025-11-20
Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants
Duke University
Available
NCT05918913 2025-09-05
Expanded Access Program for Revumenib
Syndax Pharmaceuticals
No longer available
NCT04008524 2025-08-06
A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies
Institute of Hematology & Blood Diseases Hospital, China
Available
NCT05738538 2025-06-04
Expanded Access to Ziftomenib
Kura Oncology, Inc.
Available
NCT03145545 2025-05-22
Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSC
Children's Hospital of Philadelphia
Available
NCT02158767 2025-03-12
Access Protocol. Infusion of CD34+ Enriched, T Cell Depleted Hematopoietic Stem Cell Grafts.
Case Comprehensive Cancer Center
No longer available
NCT05215405 2025-02-03
Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL
University of Texas Southwestern Medical Center
No longer available
NCT05172700 2024-12-18
Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
Eli Lilly and Company
Approved for marketing
NCT05593185 2024-12-09
Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS
Sellas Life Sciences Group
Available
NCT03420430 2024-09-25
Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care
Genelux Corporation
No longer available
NCT05219266 2024-06-28
Managed Access Programs for PKC412, Midostaurin
Novartis
No longer available
NCT03592576 2024-05-06
Expanded Access to Navitoclax
AbbVie
No longer available
NCT04757259 2024-03-19
Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib
Alexion Pharmaceuticals, Inc.
No longer available
NCT05627466 2024-02-15
US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Gilead Sciences
No longer available
NCT04518644 2023-04-28
Nilotinib, for Patients With CML-CP or CML-AP
Novartis
No longer available
NCT04559555 2022-08-09
MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Novartis
No longer available
NCT04678466 2022-05-31
Flotetuzumab Expanded Access Program
MacroGenics
No longer available
NCT02258490 2022-03-15
Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation
Emory University
No longer available
NCT03594162 2021-12-03
Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch
UNC Lineberger Comprehensive Cancer Center
No longer available
NCT04943952 2021-08-03
JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase
Jazz Pharmaceuticals
Approved for marketing
NCT01200017 2021-05-27
Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
University of California, San Francisco
No longer available
NCT03070093 2021-04-20
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Astellas Pharma Inc
Approved for marketing
NCT03723135 2020-09-18
Expanded Access for CC-486
Celgene
Approved for marketing
NCT02624570 2020-07-15
AMLFLT3
Novartis
No longer available
NCT03501615 2020-06-29
MOXE
AstraZeneca
Approved for marketing
NCT03723057 2019-10-24
Expanded Access for AG-221
Celgene
No longer available
NCT03114228 2019-10-15
An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)
Novartis
No longer available
NCT02197650 2018-12-04
EAP
ERYtech Pharma
No longer available
NCT03409081 2018-09-13
Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
Astellas Pharma Inc
No longer available
NCT03245424 2018-07-24
Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation
Agios Pharmaceuticals, Inc.
Approved for marketing
NCT01869803 2018-03-02
Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia
Wake Forest University Health Sciences
Approved for marketing
NCT01592136 2018-02-06
Expanded Access Program of Ponatinib
Takeda
Approved for marketing
NCT02437019 2017-03-20
Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Janssen-Cilag Farmaceutica Ltda.
Approved for marketing
NCT00423826 2016-02-29
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
Barbara Ann Karmanos Cancer Institute
No longer available
NCT02136511 2014-10-28
Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia
Gilead Sciences
Approved for marketing
NCT00481559 2014-01-17
Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity
BTG International Inc.
Approved for marketing
NCT01549548 2013-03-15
Compassionate Use Ponatinib
OHSU Knight Cancer Institute
No longer available
NCT00905593 2012-07-18
ENACT
Novartis
Approved for marketing
NCT00302016 2011-08-26
Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia
Novartis
No longer available
NCT00413270 2011-07-13
Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant
Novartis
No longer available
NCT00854841 2009-03-03
The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder
Pusan National University Hospital
Available